Theravance Biopharma Inc (TBPH) - Total Assets
Based on the latest financial reports, Theravance Biopharma Inc (TBPH) holds total assets worth $485.57 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Theravance Biopharma Inc - Total Assets Trend (2011–2025)
This chart illustrates how Theravance Biopharma Inc's total assets have evolved over time, based on quarterly financial data. Also see TBPH stock market capitalisation for the company's overall valuation and market capitalisation.
Theravance Biopharma Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Theravance Biopharma Inc's total assets of $485.57 Million consist of 86.2% current assets and 13.8% non-current assets. Review debt load of Theravance Biopharma Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.6% |
| Accounts Receivable | $95.54 Million | 19.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Theravance Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Theravance Biopharma Inc (TBPH) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Theravance Biopharma Inc's current assets represent 86.2% of total assets in 2025, an increase from 16.8% in 2011.
- Cash Position: Cash and equivalents constituted 34.6% of total assets in 2025, up from 0.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 19.7% of total assets.
Theravance Biopharma Inc Competitors by Total Assets
Key competitors of Theravance Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Theravance Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.93 | 5.02 | 3.39 |
| Quick Ratio | 10.93 | 5.02 | 3.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $380.16 Million | $128.98 Million | $206.58 Million |
Theravance Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between Theravance Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.78 |
| Latest Market Cap to Assets Ratio | 1.76 |
| Asset Growth Rate (YoY) | 37.1% |
| Total Assets | $485.57 Million |
| Market Capitalization | $854.78 Million USD |
Valuation Analysis
Above Book Valuation: The market values Theravance Biopharma Inc's assets above their book value (1.76x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Theravance Biopharma Inc's assets grew by 37.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Theravance Biopharma Inc (2011–2025)
The table below shows the annual total assets of Theravance Biopharma Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $485.57 Million | +37.10% |
| 2024-12-31 | $354.16 Million | -7.29% |
| 2023-12-31 | $382.00 Million | -37.11% |
| 2022-12-31 | $607.40 Million | +62.05% |
| 2021-12-31 | $374.82 Million | -20.09% |
| 2020-12-31 | $469.06 Million | +14.73% |
| 2019-12-31 | $408.83 Million | -27.03% |
| 2018-12-31 | $560.24 Million | +26.92% |
| 2017-12-31 | $441.40 Million | -30.95% |
| 2016-12-31 | $639.25 Million | +113.00% |
| 2015-12-31 | $300.12 Million | -11.15% |
| 2014-12-31 | $337.77 Million | +1241.59% |
| 2013-12-31 | $25.18 Million | +20.11% |
| 2012-12-31 | $20.96 Million | +51.67% |
| 2011-12-31 | $13.82 Million | -- |
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic n… Read more